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Abstract
Objectives. This study aimed to assess the cost-effectiveness of treatments for attention-deficit/hyperactivity disorder
(ADHD) in children through prevention of serious delinquent behavior. Cost-effectiveness was assessed in net-
monetary benefit (NMB). Methods. To evaluate the three major forms of ADHD treatment (medication manage-
ment, behavioral treatment, and the combination thereof) relative to community-delivered treatment (control condi-
tion), we used data from 448 children, aged 7 to 10, who participated in the National Institute of Mental Health’s
Multimodal Treatment Study of Children with ADHD. We developed a three-state continuous-time Markov model
(no delinquency, minor to moderate delinquency, serious delinquency) to extrapolate the results 10 years beyond the
14-month trial period at a 3% discount rate. Serious delinquency was considered an absorbing state to enable assess-
ment in life-years (LYs) of serious delinquent behavior prevented. The willingness-to-pay (WTP) threshold was set
equal to the annual cost associated with serious delinquency in children with ADHD of $12,370. Results. Modeled
and observed outcomes matched closely with a mean difference of 6.9% in LYs of serious delinquent behavior pre-
vented. The economic evaluation revealed a NMB of $95,449, $88,553, $90,536 and $98,660 for medication manage-
ment, behavioral treatment, combined treatment, and routine community care, respectively. Estimates remained
stable after linearly increasing the WTP threshold between $0 and $50,000 in the deterministic sensitivity analyses.
Conclusions. This study assessed the cost-effectiveness of treatments for ADHD in children using continuous-time
Markov modeling. We show that treatment evaluation in broader societal outcomes is essential for policy makers, as
the three major forms of ADHD treatment turned out to be inferior to the control condition.
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Attention-deficit/hyperactivity disorder (ADHD) is a
neurodevelopmental disorder characterized by develop-
mentally inappropriate and impairing inattention, hyper-
activity, and impulsivity, mostly seen and diagnosed in
children and adolescents.1,2 According to the most recent
meta-analysis of Polanczyk et al.3 of 41 studies in 27
countries from every world region, the prevalence of
ADHD in children and adolescents is estimated around
3.4%. Academic failure, poor self-esteem, troublesome
peer and family relationships, substance abuse, and delin-
quent behavior are associated with ADHD, and patients
are often diagnosed with one or more co-occurring
This Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
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psychiatric disorders.1,2,4,5 The majority of children and
adolescents diagnosed continue to have impairing symp-
toms into adulthood.1,2,5 The negative impact of ADHD
within and beyond the health system during childhood
and the long-lasting impact into adulthood result in sig-
nificant long-term personal and societal costs.6–9
The major treatments to mitigate the related (economic)
burden of ADHD are medication management and beha-
vioral treatment, alone or in combination.10 Jensen et al.
evaluated the cost-effectiveness of these treatments using
data from the National Institute of Mental Health’s
(NIMH) Multimodal Treatment Study of Children with
ADHD (MTA study),11 in which 579 children with
ADHD were assigned to 14 months of controlled medica-
tion management, behavioral treatment, the combination
of medication management, and behavioral treatment
(also referred to as combined treatment), or routine com-
munity care (control condition).10–12 The cost-effectiveness
of medication management proved superior to behavioral
treatment at the end of the 14-month trial.11 The com-
bined treatment is less superior than medication manage-
ment due to the considerable increase in costs associated
with behavioral treatment.11 We build on this study by
focusing on the cost-effectiveness beyond the trial period
of the MTA study. Hence, a decision model was developed
to evaluate the 10-year cost-effectiveness of the treatments
of the MTA study.
Contrary to previous Markov models for ADHD
treatment evaluation,13–16 we propose a different model
structure. First, ADHD is a chronic condition that
makes a full remission state unlikely. Second, the level of
ADHD symptoms tend to be highly persistent over
time.17,18 Thus, decision models with diseases states
based on ADHD symptoms end up with extremely low
or high transition probabilities, which limits the applic-
ability of the model. Third, treatments for ADHD are
mostly evaluated in terms of symptomatic outcomes,
while the (economic) burden of ADHD often extends to
society at large.6–9 For example, antisocial behaviors and
delinquency associated with ADHD result in significant
costs for society.19–21 Specifically, D’Amico et al. demon-
strated that conduct disorders in childhood are associ-
ated with a two- to threefold increase in early adulthood
costs, mainly driven by criminal acts and judicial con-
tacts.22 Therefore, we defined delinquency states for our
decision model. Importantly, delinquency is a distinct
indicator for children’s behavior and partaking in soci-
ety. Also, robust correlations between delinquency and
the level of ADHD symptoms are found in the litera-
ture.23–25 Fourth, we followed common practice and
based the extrapolation on data within the trial period of
the MTA study. Subsequently, contrarily to previous
studies, we used follow-up data to assess the accuracy of
the model’s long-term prediction to ensure reliability of
modeling estimates in future economic evaluation.
Finally, the previous Markov models for ADHD treat-
ment evaluation consider discrete time periods.13–16
Consequently, changes in states occur only at the begin-
ning or end of predefined time intervals.26 We have
relaxed this assumption to build our model in continuous
time. This relaxation was previously shown to result in
more accurate estimates.27
Methods
NIMH’s Multimodal Treatment Study of
Children With ADHD (MTA Study)
For this study, we used data from the MTA study, a
multi-site randomized controlled trial that was con-
ducted in the United States and was designed to evaluate
the major forms of ADHD treatment.10,12 Children had
been randomly assigned to one of the three active
treatments—medication management, behavioral treat-
ment, or the combination thereof (hereafter combined
treatment)—or routine community care. Routine com-
munity care is the control condition and reflects the
nature of less intensive (and less costly) community-
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delivered treatment. The MTA study involved 14 months
of controlled treatment in 579 children with ADHD,
aged 7 to 10 years, with naturalistic follow-ups for up to
16 years after the end of the trial period. Follow-up
assessments were carried out during childhood (2 and 3
years after baseline), (late-)adolescence (6, 8, and 10
years after baseline), and adulthood (12, 14, and 16 years
after baseline). We used the follow-up data of childhood
and late-adolescence periods, since our modeled outcome
variable (delinquency) was not assessed in adulthood.
Summary statistics of the baseline characteristics age,
gender, comorbidity, intelligence, ethnic background,
and occupation-based socioeconomic family status are
presented in Table 1.
Comorbidity is a dummy variable that equals 1 for
the presence of anxiety and/or depression. Intelligence is
the child’s total intelligence quotient (IQ) measured with
the Wechsler Intelligence Scale for Children–III (WISC-
III). Ethnic background is a dummy variable that equals 1
for children from a non-Caucasian background. Finally,
occupation-based socioeconomic family status is a dummy
variable that equals 1 for children from a high socioeco-
nomic family status. Further details on the four treatment
modes of the MTA study and other baseline characteristics
are available in previous publications.10,12,28,29 All study
procedures had been approved by institutional review
boards and were carried out in accordance with the
Declaration of Helsinki. Participants and parents were
informed of the procedures and provided written informed
consent.10
Delinquency
In this study, a six-point scale on delinquency was used
as primary outcome variable,29 coded ordinally from
two parent-report measures, the DISC-IV-CD Module
and the Parent DSM-IV Aggression and Conduct
Disorder Rating Scale,30 and two self-report measures.
Specifically, the Self-Reported Antisocial Behavior ques-
tionnaire31 at the 2-year assessment and the Self-
Reported Delinquency questionnaire32 at the 3-year
assessment. By using all available procedures partici-
pants were assigned (retrospectively) a delinquency clas-
sification code at each assessment point.33–36 The coding
scheme of the Pittsburg Youth Study was used to con-
tribute items to each code.35,36
The delinquency scale was then categorized as follows:
0 = no delinquency; 1 = minor delinquency only at
home (e.g., theft of less than $5 or vandalism); 2 = minor
delinquency outside of the home (e.g., vandalism, cheat-
ing someone, shoplifting less than $5); 3 = moderately
serious delinquency (e.g., vandalism, theft of $5 or more,
carrying a weapon); 4 = serious delinquency (e.g., break-
ing and entering, drug selling, attacking someone with
the intent to seriously hurt or kill, rape); 5 = engagement
in two or more different level 4 offences. This variable
was assessed at baseline, after the 14-month trial period,
and at the follow-up assessments after 2, 3, 6, and 8
years.
Markov Model
To predict the trajectories of delinquent behavior during
adolescence in relation to the four treatment modes of
the MTA study, we developed a continuous-time
Markov model26 based on three delinquency states
(Figure 1): no delinquency (state 1), minor to moderate
delinquency (state 2), and serious delinquency (state 3).
The states were discerned based on the delinquency scale
mentioned above, in which a 0 score was considered no
delinquency, 1 to 3 scores minor to moderate delin-
quency, and scores 4 and 5 were considered serious
delinquency.
The specification, parameter estimation, and evalua-
tion of this model were conducted using vertical model-
ing formulation37 based on a previously suggested
framework.38 Briefly, this includes the specification of
the Markov process by means of two main parameters:
1) sojourn time distributions and 2) the probabilities of
the next state visited (also referred to as the future state
probabilities). The estimation of the parameters are sub-
sequently conducted in which the treatment indicator



















IQ, intelligence quotient; SD, standard deviation; WISC, Wechsler
Intelligence Scale for Children.
aInference: * indicate significant differences at the 5%/1% level based
on the mean differences of the two samples, assessed with a t test.
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can easily be incorporated in the corresponding para-
metric survival and multinomial regression models.
Finally, the modeled outcomes can be evaluated using
Monte-Carlo simulation of the whole procedure.
To assess the cost-effectiveness of the treatments
through prevention of serious delinquent behavior, we
considered serious delinquency to be an absorbing state.
This assumption does not allow participants to either
make transition out of this state (i.e., decrease the delin-
quency level after entering the serious delinquency state)
or start in this state (i.e., enrolling in this study with
delinquency levels 4 or 5). Consequently, within the total
sample size of 579 children, our Markov model was built
based on the delinquency data from 448 children. The
reason for exclusion of these 131 children was that they
either already had a 4 or 5 delinquency score when enrol-
ling in the study or follow-up data was missing.
Exponential survival models were subsequently used
to estimate the cumulative distribution functions of the
sojourn time in both states 1 and 2 (Fi uð Þ, i= 1, 2). The
future state probabilities (pij, i= 1, 2; j= 1, 2, 3; i 6¼ j)
were estimated by fitting logistic regression models to the
event indicator of entering the serious delinquency state
from the no delinquency state p13 and from the minor to
moderate delinquency state p23. The transition probabil-
ities between the no delinquency state and minor to mod-
erate delinquency state can then be calculated using one
minus the two previously mentioned two probabilities.
The treatment indicator was incorporated as the covari-
ate in both exponential survival models and the logistic
regression models.
We developed our model based on the individual trajec-
tory of delinquency seriousness within the trial period, as
we use the 10-year follow-up data to validate accuracy of
long-term prediction. The outcome of our model is the
average time of not reaching the serious delinquency state,
defined the same as the life-years (LYs) of serious delin-
quent behavior prevented. Model performance was subse-
quently internally validated by comparing the predicted
(average across 100,000 simulation runs) probability of
serious delinquent behavior prevented (based on Kaplan-
Meier estimate) to the observed empirical survival curves
with the same outcome variable.39 The simulated results
reflected a 10-year time horizon. The available follow-up
data in the MTA study enables the unique opportunity to
internally validate the modeling prediction at 10-year
follow-up for the four different treatments.
Economic Evaluation
We included treatment costs in which the following three
components were taken into account: medication cost,
visit cost for teachers and aides, and cost of psychiatrist,
psychologist, and pediatrician. Per treatment group, we
converted the longitudinal costs into daily costs. The
respective resulting daily costs were $0.52 for routine
community care, $0.62 for medication management,
$3.18 for behavioral treatment, and $3.53 for the com-
bined treatment. Total treatment costs were calculated
by multiplying the LYs of serious delinquent behavior
prevented and the daily costs. The annual rate of dis-
counting was set at 3% for both cost and effectiveness
outcomes.40 We compared the cost-effectiveness out-
comes among the treatments in terms of a net-monetary
benefit (NMB) framework.41 The willingness-to-pay
(WTP) threshold was set equal to the annual cost associ-
ated with serious juvenile delinquency in children with
ADHD retrieved from previous research in the United
States.6 Specifically, criminal history was assessed
through self-report, including crimes, juvenile detention,
probation, and jail. The costs of crimes incurred by vic-
tims and costs to the criminal justice system were esti-
mated based on information from the Bureau of Justice
Statistics, the Federal Bureau of Investigation, and the
Criminal Justice Institute. The mean total criminal costs
were $12,868 and $498 for children with and without
ADHD, respectively. Hence, we incorporated the
adjusted difference of $12,370 as WTP threshold. As
such, we incorporated the cost avoided in the serious
delinquency state in the economic evaluation. The cost-
effectiveness can then easily be calculated within this
framework as follows:
Figure 1 Schematic Representation of the Markov Model.
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NMB=mean prevented LYs3WTP
mean total treatment cost ð1Þ
The WTP threshold is a key parameter for the NMB
analysis, hence determining the conclusions drawn from
the economic evaluation. Therefore, we reevaluated
Equation (1) in deterministic sensitivity analyses with line-
arly increasing WTP thresholds between $ 0 and $50,000.
Further Analyses
We used logistic regression models to control for sample
selection and the likelihood of absorbance. In the first
model, we controlled for the effect of sample selection by
estimating odds ratios (ORs) of model exclusion condi-
tional on the relevant covariates age, gender, comorbidity,
intelligence, ethnic background, and occupation-based
socioeconomic family status. We established whether the
covariates mentioned above were independent predictors
for model exclusion at a 5% significance level. In the sec-
ond model, we focused on the likelihood of the absor-
bance in the serious delinquency state. We compared the
adjusted OR of absorbance in the serious delinquency
state with moving out of this state at a 5% significance
level for both the included and excluded children. All of
above statistical analyses were performed with R 3.2.4 (R
Foundation; https://www.r-project.org/foundation/) and
STATA/SE 15.0 (STATA; https://www.stata.com/).
Results
Model Validation
The model parameter estimation results are presented in
Table 2. As is shown in Figure 2, the predicted survival
curves obtained from our Markov model closely
resembled the observed survival curves. The only excep-
tion was the curve for children who were assigned to
medication management, in which a clear overestimation
of the probability of preventing serious delinquent beha-
vior was detected. Our model provided excellent predic-
tions for children assigned to routine community care
and the combined strategy of medication management
and behavioral treatment. Specifically, the mean differ-
ence in percentage of LYs of serious delinquent behavior
prevented between the modeled and observed trajectories
is 8.5% for medication management, 7.8% for beha-
vioral treatment, 5.8% for the combined treatment, and
5.7% for routine community care.
Table 2 The Specification and the Results of the Parameter Estimation for the Markov Modela
Markov Model a bTT
F1(u)
T1 6.89 (0.22)
T2 6.89 (0.22) 0.08 (0.32)
T3 6.89 (0.22) 0.13 (0.32)
T4 6.89 (0.22) 20.10 (0.30)
F2(u)
T1 7.01 (0.17)
T2 7.01 (0.17) 20.16 (0.22)
T3 7.01 (0.17) 20.02 (0.24)
T4 7.01 (0.17) 20.15 (0.22)
p13
T1 23.13 (1.10)
T2 23.13 (1.10) 0.61(1.25)
T3 23.13 (1.10) 0.64 (1.25)
T4 23.13 (1.10) 0.07 (1.44)
p23
T1 23.13 (0.67)
T2 23.13 (0.67) 0.20 (0.49)
T3 23.13 (0.67) 0.23 (0.50)
T4 23.13 (0.67) 20.33 (0.54)
F1(u;l)=F2(u; l)= 1 exp ( lu)
l= exp ( a bTT )

u p13ð Þ=a+bTT +bGG
u p23ð Þ=a+bTT +bGG

aStandard errors in parentheses; T2, T3, T4, respectively, represent routine community care, medication management, behavioral treatment and
combined treatment, with routine community care as the reference category for bTT ; u(p) = log(p/(1 2 p)) is the logit function.
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Figure 2 Results of the model validation for the four treatment modes: (a) routine community care, (b) medication management,
(c) behavioral treatment, (d) combined treatment; straight lines represent observed data, and dashed lines represent the model
prediction.
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Economic Evaluation
Thirty-two of the 448 children (7%), who started at base-
line in the no delinquency or mild to moderate delin-
quency state, reached the serious delinquency state
within 10 years. For policy makers this is a substantial
percentage, looking at the description of the delinquency
levels associated with this state and taking into account
the annual cost associated with serious juvenile delin-
quency in children with ADHD of $12,370.6 Table 3 pre-
sents the cost-effectiveness results stratified by the four
treatment modes considered in the MTA study. We per-
formed both undiscounted and discounted analyses.
In 10 years time, the discounted average LYs of seri-
ous delinquent behavior prevented were 7.86 for medica-
tion management, 7.90 for behavioral treatment, 8.17 for
the combined treatment, and 8.10 for routine community
care. Although the combined treatment had the highest
LYs prevented, routine community care turned out to be
the optimal strategy in terms of cost-effectiveness with
the highest mean NMB due to the substantial difference
in treatment cost.
Figure 3 illustrates that the difference in NMB between
routine community care and the two active treatments med-
ication management and behavioral treatment increases as
Table 3 Results of the Economic Evaluation Stratified by Treatment Mode
Treatment Mode Mean Total Cost ($) Mean LYs Prevented (Years) Mean NMB ($)
Undiscounted
a. Routine community care 1,769 9.32 113,519
b. Medication management 2,043 9.03 109,658
c. Behavioral treatment 10,539 9.08 101,781
d. Combined treatment 12,111 9.40 104,167
Discounted
a. Routine community care 1,537 8.10 98,660
b. Medication management 1,779 7.86 95,449
c. Behavioral treatment 9,170 7.90 88,553
d. Combined treatment 10,527 8.17 90,536
LY, life-year; NMB, net monetary benefit.
Figure 3 NMB plot with linearly increasing WTP thresholds between $ 0 and $50,000.
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the WTP increases, while the difference in NMB between
routine community care and the combined treatment
reduces. The latter is due to the fact that the difference in
treatments cost becomes, relatively, less determinative for
the NMB results.
Further Analyses
Table 4 demonstrates that the results are not driven by
sample selection, as none of the ORs of model exclusion
conditional on the relevant covariates age, gender, comor-
bidity, intelligence, ethnic background, or occupation-
based socioeconomic family status were statistically sig-
nificant at a 5% level.
Furthermore, we determined the likelihood of absor-
bance in the serious delinquency state once a child
entered this state. We found for the 448 included chil-
dren an adjusted OR of continuation in the serious delin-
quency state of 1.471 (P \ 0.001), against an adjusted
OR of moving out the serious delinquency state of
21.423 (P \ 0.001). Similarly, we found for the 131
excluded children an adjusted OR of continuation in the
serious delinquency state of 0.927 (P \ 0.001), against
an adjusted OR of moving out the serious delinquency
state of 20.953 (P \ 0.001). Hence, the serious delin-
quency state is more likely absorbent than transient for
both groups.
Discussion
In this study we assessed the long-term cost-effectiveness
of the three major forms of ADHD treatment and rou-
tine community care beyond the 14-month trial period of
the MTA study.12 For this we developed a Markov
model with an innovative model structure. We consid-
ered the high-cost serious delinquency state to be absorb-
ing to predict the LYs of serious delinquent behavior
prevented over a time period of 10 years. The availability
of long-term follow-up data in the MTA study enabled
us to assess the accuracy of modeling prediction.
Modeled and observed outcomes matched closely with a
mean difference of 6.9%. Hence, the model delivers reli-
able estimates when used in future economic evaluations.
By setting the WTP equal to the cost avoided in the seri-
ous delinquency state, we calculated cost-effectiveness in
terms of NMB.41 Results of the economic evaluation
revealed that the combined treatment was the only active
treatment mode that further decreases serious delinquent
behavior compared with routine community care.
However, the substantial difference in treatment cost
renders the routine community care to be the optimal
treatment strategy in terms of NMB. Moreover, results
are robust to manipulating the WTP threshold in deter-
ministic sensitivity analyses.
These findings are in line with previous research with
the MTA study.28,29 Molina et al. demonstrated that
while after 3 years the active ADHD treatments had
improved symptomatic symptoms of the children relative
to the control condition, no differences were found with
respect to delinquent behavior.28,29 Although the MTA
study was not originally designed to examine delinquency,
we argue that it is interesting for policy makers to see
whether the pursued medical effects of the treatments
translate into positive effects with respect to behavior of
these children in society. Clearly, the economic impact of
ADHD often extends to society beyond the health sys-
tem6–9 and treatment effects on ADHD symptoms and
broader societal aspects of the disorder differ substan-
tially.28,29 Additionally, Schawo et al.15 plead for model-
based studies in ADHD using empirical data for model
validation and broader societal outcomes as the modeled
outcome. As such, the evaluation form in this study has
its potential to be extended to a broader perspective.
One of the innovative structures of the Markov model
in this study is the use of a more or less transient state in
real life as absorbing state in the model. As such, it
Table 4 Logistic Regression Results on Model Exclusiona
Model Exclusion Indicator Odds Ratios Marginal Effects
Age 20.232 (0.1237) 20.041 (0.0214)
Female 0.266 (0.2607) 0.046 (0.0454)
Comorbidity 20.083 (0.2301) 20.014 (0.0401)
Intelligence, WISC-III IQ 20.007 (0.0076) 20.0012 (0.0013)
Non-Caucasian background 0.090 (0.2109) 0.016 (0.0368)
High occupation-based socioeconomic family status 0.094 (0.2224) 0.016 (0.0388)
IQ, intelligence quotient; WISC, Wechsler Intelligence Scale for Children.
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enables model validation according to the guidelines for
simulating a continuous-time Markov model.26 Without
including an absorbing state, the simulation along with
our vertical modeling approach reaches an endless pro-
cess. The only reason for a process to end is when the
processing time is beyond our study time horizon of 10
years. Furthermore, with this model structure we were
able to evaluate the treatments of the MTA study
through prevention of serious delinquent behavior. The
latter is highly relevant for policy makers as serious
delinquency is associated with substantial societal
cost.19–21 A limitation of this assumption is that we had
to delete 22.6% of the original sample. However, we
demonstrated that this assumption did not affect the
modeled outcomes, as model exclusion was not predicted
by the relevant child and family characteristics of age,
gender, comorbidity, intelligence, ethnic background,
and occupation-based socioeconomic family status.
Moreover, results revealed that the serious delinquency
state is more likely absorbent than transient for both
included and excluded children.
In this study we included additional covariates to con-
trol the sensitivity of our modeling assumptions.
Exploring the effect of these child and family characteris-
tics on juvenile delinquency in children with ADHD is
beyond the scope of this study, but remains an interest-
ing topic for further research.
Conclusions
This study assessed the cost-effectiveness of treatments
for ADHD in children using a continuous-time Markov
model. The structure of the model allowed to evaluate
the treatments through prevention of serious delinquent
behavior over a time period of 10 years. The three major
forms of ADHD treatment had a lower NMB than rou-
tine community care, which confirms the necessity for
policy makers to evaluate ADHD treatments in broader
societal outcomes before implementation.
ORCID iD
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